Altea, Amylin and Lilly to develop first transdermal exenatide
This article was originally published in Scrip
Executive Summary
Altea Therapeutics has signed a deal worth up to $46 million with Amylin Pharmaceuticals and Lilly to develop and commercialise the first transdermal exenatide patch for type 2 diabetes. Lilly and Amylin market exenatide, a first-in-class GLP-1 analogue, as Byetta.